Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMGEN GAMMA INTERFERON U.S. CLINICAL TRIALS ARE THE FIRM's FIRST -- ANNUAL REPORT

Executive Summary

Amgen's first therapeutic product to enter clinical trials is recombinant DNA gamma interferon, which the firm began testing in humans earlier this year, according to Amgen's 1985 annual report. Gamma interferon is one of four human therapeutic agents which Amgen says will be in clinical testing by the end of the year. One of the four, Consensus interferon, is reported to have "five to ten times the potency of any known alpha interferon," the annual report states. The company has indicated that animal studies have shown that the product allows lower doses than alpha while achieving greater antitumor and antiviral activity. In May 1984, Amgen entered into a 50-50 joint venture with the Japanese beer mfr., Kirin, for the production and worldwide marketing of erythropoietin (EPO), a hormone responsible for controlling red blood cell production ("The Pink Sheet" May 21, 1984, p. 19). According to the report, EPO is expected "to be of significant therapeutic benefit to kidney dialysis patients." Amgen will manufacture EPO at its new Thousand Oaks production facility and market the product in the U.S., while Kirin will do so in Japan. The two firms will jointly market EPO in the rest of the world, the report states. Another product in the Amgen pipeline is a recombinant hepatitis B vaccine, which the company says it will be able to produce "at a lower cost than any other known competing product." The report notes that the largest potential market for the vaccine is the Far East, where there will be "in excess of 100 mil. doses per year for the foreseeable future." Finally, the company is also working on a rDNA interleukin-2 product, which it says may be effective in treating white cell depression.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel